Literature DB >> 1555976

Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer.

T J Whelan1, A J Dembo, R S Bush, J F Sturgeon, S Fine, J F Pringle, G A Rawlings, G M Thomas, J Simm.   

Abstract

We examined the records of 105 patients with advanced ovarian cancer who had been treated with cisplatin combination chemotherapy followed by abdominopelvic radiotherapy. The purpose was to define the morbidity of this approach, and identify those factors predictive of toxicity. Acute toxicity resulting in delay or failure to complete treatment was most commonly due to myelosuppression. Nine of 105 patients (8.6%) required surgery for bowel obstruction that was not due to recurrent disease, 3 had an episode of bowel obstruction that settled conservatively, and a further 5 underwent surgery for obstruction due to recurrent tumor. The presence of both a dose of abdominopelvic radiotherapy over 2250 cGy, as well as a second-look laparotomy prior to radiotherapy, was associated with an increased risk of serious bowel complications. The increased frequency of late bowel morbidity seen in the combined modality group is likely explained by the presence of these two factors, rather than the exposure to chemotherapeutic agents per se. These observations are supported by the published literature.

Entities:  

Mesh:

Year:  1992        PMID: 1555976     DOI: 10.1016/0360-3016(92)90779-h

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.

Authors:  Nathalie Rochet; Katja Lindel; Sonja Katayama; Kai Schubert; Klaus Herfarth; Andreas Schneeweiss; Christoph Sohn; Wolfgang Harms; Juergen Debus
Journal:  Strahlenther Onkol       Date:  2015-03-19       Impact factor: 3.621

2.  Whole abdomen radiation therapy in ovarian cancers: a comparison between fixed beam and volumetric arc based intensity modulation.

Authors:  Umesh Mahantshetty; Swamidas Jamema; Reena Engineer; Deepak Deshpande; Rajiv Sarin; Antonella Fogliata; Giorgia Nicolini; Alessandro Clivio; Eugenio Vanetti; Shyamkishore Shrivastava; Luca Cozzi
Journal:  Radiat Oncol       Date:  2010-11-15       Impact factor: 3.481

3.  Whole abdominal radiotherapy in ovarian cancer.

Authors:  Alberto Biete; Izaskun Valduvieco; Angels Rovirosa; Blanca Farrús; Francesc Casas; Carlos Conill
Journal:  Rep Pract Oncol Radiother       Date:  2010-03-23

4.  Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.

Authors:  Nathalie Rochet; Meinhard Kieser; Florian Sterzing; Sonja Krause; Katja Lindel; Wolfgang Harms; Michael H Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus
Journal:  BMC Cancer       Date:  2011-01-28       Impact factor: 4.430

5.  Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes.

Authors:  Nathalie Rochet; Rachel S Kahn; Andrzej Niemierko; Thomas F Delaney; Anthony H Russell
Journal:  Radiat Oncol       Date:  2013-10-14       Impact factor: 3.481

6.  Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study.

Authors:  Nathalie Arians; Meinhard Kieser; Laura Benner; Nathalie Rochet; Lars Schröder; Sonja Katayama; Klaus Herfarth; Kai Schubert; Andreas Schneeweiss; Christof Sohn; Katja Lindel; Jürgen Debus
Journal:  Radiat Oncol       Date:  2019-10-21       Impact factor: 3.481

7.  Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.

Authors:  Nathalie Rochet; Alexandra D Jensen; Florian Sterzing; Marc W Munter; Michael H Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus; Wolfgang Harms
Journal:  BMC Cancer       Date:  2007-12-19       Impact factor: 4.430

8.  Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis.

Authors:  Lushi Yu; Hongyun Gong; Qian Li; Honggang Ren; Yi Wang; Haihua He; Tian Li; Qibin Song
Journal:  J Oncol       Date:  2021-02-11       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.